Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
DASH
2024-514615-10-01Phase 2Authorised
- Sponsor
- Radboud University Medical Center
- Start
- Jan 2025
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, randomised trial in subarachnoid hemorrhage (SAH) comparing Deferoxamine with Placebo (NaCl 0.9%) (2 arms). Primary endpoint: Presence of new ischemia on control imaging at 2 weeks and 6 months. Planned start Jan 2025; status: authorised.
02
Drugs
deferoxamine
03
Conditions
subarachnoid hemorrhage (SAH)
Beyond the preview
Go deeper on 2024-514615-10-01.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2024-514615-10-01.